News

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...
This new article publication from Acta Pharmaceutica Sinica B, discusses a bispecific killer engager for targeted depletion ...